Iron deficiency after Roux-en-Y Gastric Bypass: insufficient iron absorption from oral iron supplements

Ina GESQUIERE, PharmD; Matthias LANNOO, M.D.; Patrick AUGUSTIJNS, PhD PharmD; Christophe MATTHYS, PhD; Bart VAN DER SCHUEREN, PhD M.D.; Veerle FOULON, PhD PharmD

Manuscript type: Original contribution

Correspond to: Ina Gesquiere

Ina Gesquiere

e-mail: ina.gesquiere@pharm.kuleuven.be

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

O&N2, Herestraat 49, box 521

3000 Leuven

Belgium

Tel: + 32 16 32 34 47

Fax: + 32 16 32 34 68

Authors:

Matthias Lannoo

e-mail: matthias.lannoo@uzleuven.be

Department of Abdominal Surgery

UZ Leuven Campus Gasthuisberg

Herestraat 49

3000 Leuven

Belgium

Patrick Augustijns

e-mail: patrick.augustijns@pharm.kuleuven.be

Department of Pharmaceutical and Pharmacological Sciences

O&N2, Herestraat 49 box 921

3000 Leuven

Christophe Matthys

e-mail: christophe.matthys@uzleuven.be

Laboratory of Clinical and Experimental Endocrinology

UZ Leuven Campus Gasthuisberg

Herestraat 49, box 7003

3000 Leuven

Bart Van der Schueren

e-mail: bart.vanderschueren@uzleuven.be

Laboratory of Clinical and Experimental Endocrinology

UZ Leuven Campus Gasthuisberg

Herestraat 49, box 902

3000 Leuven

Veerle Foulon

e-mail: veerle.foulon@pharm.kuleuven.be

Department of Pharmaceutical and Pharmacological Sciences

O&N2, Herestraat 49, box 521

3000 Leuven

Belgium

Running head: Iron absorption after RYGB

Acknowledgements

Ina Gesquiere receives a PhD scholarship from the Agency for Innovation by Science and Technology, Flanders, IWT-111328. The authors declare no conflict of interest.

Abstract

Background Roux-en-Y gastric bypass (RYGB) may reduce the absorption of iron, but the extent to which this absorption is impeded is largely unknown. First, we determined the prevalence of iron deficiency following RYGB and explored the risk factors for its development. Second, we examined to what extent oral iron supplements are absorbed after RYGB.

Methods Monocentric retrospective study in 164 patients (123 female, 41 male; mean age 43 years) who underwent RYGB between January 2006 and November 2010. Pre-and postoperative data on gender, age, BMI, serum levels of iron, ferritin, hemoglobin, vitamin B12, 25-hydroxy vitamin D, and use of proton pump inhibitors and H₂-antagonists were collected. Generalized linear mixed models were used for the analysis of the data. In 23 patients who developed iron deficiency after surgery, an oral challenge test with 100 mg FeSO₄.7H₂O was performed.

Results Following RYGB, 52 (42.3%) female patients and 9 male (22.0%) patients developed iron deficiency (serum ferritin concentration ≤ 20 $\mu\text{g/L}$). The prevalence of iron deficiency was significantly higher in females than males ($p=0.0170$). Young age ($p=0.0120$), poor preoperative iron status ($p=0.0004$), vitamin B12 deficiency ($p=0.0009$) and increasing time after surgery ($p<0.0001$) were also associated with iron deficiency. In the oral iron challenge test, only one patient out of 23 showed sufficient iron absorption.

Conclusions Iron deficiency is extremely frequent after RYGB and is linked with different risk factors. Iron supplementation seems essential, but the effect of oral tablets may be limited as absorption of oral iron supplements is insufficient post-RYGB.

Keywords

Bariatric surgery – iron deficiency – oral iron supplements – iron absorption

Introduction

Over the last decades, there has been an increase in the prevalence of obesity, which is now considered a global epidemic [1]. As a consequence, the number of Roux-en-Y gastric bypasses (RYGB) performed has also surged, as it is currently the only intervention in combination with lifestyle modifications which achieves major and sustainable weight reduction [2]. However, RYGB may be associated with nutritional deficiencies [3]. Deficiencies in iron, vitamin B12, folic acid, vitamin D and calcium are the most common manifestations of nutritional problems post-RYGB, some of which can result in severe complications such as anemia [4-6]. Iron deficiency has been reported in 20 to 49% of patients following RYGB [7;8]. This deficiency can be explained by three factors: 1) diminished gastric acid secretion, which is necessary for the absorption of iron; 2) reduced intestinal absorption surface, particularly the excision of the duodenum, the main absorption site of iron; and 3) low tolerance to red meat, a major source of iron. [3;9;10;11].

Therefore, patients after RYGB are routinely recommended to take prophylactic oral iron supplements [12]. Unfortunately, even upon correct administration of iron tablets, oral replacement therapy (usually with up to 300 mg of elemental iron per day in 3 or 4 iron tablets [13]) often fails to correct the deficiency in a large proportion of patients.

The objectives of the current study were twofold: 1) to determine the prevalence of iron deficiency post-RYGB and explore potential risk factors by evaluating the association between ferritin status and gender, BMI, age, time since surgery, medication use and other vitamin deficiencies and 2) to assess absorption of iron after a standardized oral challenge test in iron deficient patients after surgery.

Methods

Retrospective analysis of patient records

A first part of the study (performed in March 2011) consisted of a retrospective analysis of records of patients who had undergone a RYGB between January 2006 and November 2010 in the University Hospitals Leuven, Belgium. In all patients a laparoscopic gastric bypass with an alimentary limb of 120cm and a small gastric pouch was performed.

For each patient, data were collected from the preoperative consultation and, dependent on the time of the surgery, from the consultations at 6, 12, 24, 36, 48 and 60 months postoperative, if available. There were no limits regarding gender or age. Patients who had undergone a previous bariatric surgery were excluded from the study.

The following parameters were included into the analysis: gender, age, BMI, serum levels of iron, ferritin, hemoglobin, vitamin B12, and 25-hydroxy vitamin D. Furthermore, we included the use of proton pump inhibitors, H₂-antagonists or antacids.

If the ferritin level at some point during follow-up (ranging between 6 and 60 months) was $\leq 20 \mu\text{g/L}$, the patient was considered to suffer from iron deficiency. Anemia was defined as hemoglobin $\leq 12 \text{ g/dL}$ in women and $\leq 14 \text{ g/dL}$ in men, and vitamin B12 deficiency was defined as serum concentration of vitamin B12 $\leq 180 \text{ ng/mL}$.

The study was approved by the Medical Ethics Committee of the University Hospitals Leuven.

Oral challenge test

Twenty-three patients from the retrospective study who had developed iron deficiency (ferritin level $< 20 \mu\text{g/L}$) after RYGB, received an oral challenge test with 100 mg $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ [14]. These oral iron absorption tests were conducted as a standard procedure in clinical practice before initiating intravenous iron. The patients did not use iron supplements

and did not receive a transfusion of red blood cells during the three weeks preceding the oral challenge test. One week before the test, the use of proton pump inhibitors, H₂-antagonist, antacids and vitamin supplements was discontinued.

Patients remained fasted during the entire test. In the fasted state (t=0), a blood sample was collected to determine serum iron, ferritin, transferrin and transferrin saturation. Subsequently, a capsule containing 100 mg FeSO₄.7H₂O was administered with a glass of water. After the ingestion of iron, blood samples were taken at t=1h, 2h and 3h. The estimation of the extent of the intestinal absorption of iron was determined as the difference between the highest serum iron concentration obtained 1, 2 or 3h following the ingestion of iron, and the serum iron concentration at t=0. An increase of 80 µg/dL was considered to be representative for sufficient iron absorption [14].

Statistical analysis

Variables are summarized by means and standard deviations (SD). The data contain longitudinal measurements on the patients with assessments made at preoperative consultation and at 6, 12, 24, 36, 48 and 60 months postoperative. Nevertheless, not for all patients data are available at all time points due to missing information in files, missed consultations or closing of data collection. Summary statistics are based on available data and restricted to records with available ferritin measurement. Generalized linear mixed models (GLMM) were used for the analysis of the data, with iron deficiency as binary response variable, and a random intercept accounting for correlation between repeated measurements coming from the same patient. Inference is likelihood-based and valid if drop-out is missing at random (MAR), in the sense that missingness may depend on previous outcomes or covariates but no further on unobserved outcomes [15]. Covariate effects are presented as odds ratios (OR) and their 95% confidence intervals (CI). Effects were considered to be statistically significant when p<0.05.

The analyses were performed using the NLMIXED procedure in SAS, version 9.2 of the SAS System for Windows.

Results

Prevalence of iron deficiency post-RYGB and predictive parameters

Data from 164 patients were collected: 123 female (75.0%) and 41 male (25.0%), mean age of 43 years (SD 10 years), and mean BMI of 41.8 kg/m² (SD 4.9 kg/m²). An overview of the clinical measurements at the different moments is shown in table 1.

[Insert table 1]

After surgery, 61 patients (37.2%) developed iron deficiency at some point during follow-up after surgery (follow-up duration varying between 6 months and 5 years): 52 (42.3%) female patients and 9 male (22.0%) patients. The probability for males to develop iron deficiency post-RYGB was significantly lower compared to females (OR=0.18 [95% CI 0.04-0.73]; p=0.017). Low iron status resulted in anemia in fifteen out of 52 women (29%) and 5 out of 23 men (22%) post-RYGB.

This study also shows that the younger the patient, the higher the probability for suffering from iron deficiency after RYGB (OR per year increase in age=0.94 [95% CI 0.90-0.99]; p=0.012); this effect was the same in both sexes. Furthermore, patients with an existing iron deficiency before surgery had a much higher probability to suffer from iron deficiency postoperative compared to patients without a baseline iron deficiency (OR=19.49 [95% CI 3.96-95.99]; p=0.0004). The prevalence of iron deficiency was also higher when patients had a vitamin B12 deficiency (OR=3.78 [95% CI 1.74-8.21]; p=0.0009), both the moments before and after RYGB.

The risk of developing iron deficiency post-RYGB increased over time (OR=1.06 [95% CI 1.03-1.08] for one month increase; p<0.0001); this trend was the same in both sexes. The prevalence of iron deficiency was considerably increased from 24 months after surgery

onwards. Figure 1 shows the predicted probability of ferritin deficiency by time after the surgery.

[Insert figure 1]

There was no evidence for a relationship between the probability of developing iron deficiency and the amount of weight loss (OR=0.98 [95% CI 0.96-1.01]; $p=0.13$) or vitamin D deficiency (OR=0.60 [95% CI 0.20-1.80]; $p=0.36$). When the group of patients who did take proton pump inhibitors or H₂-antagonists was compared with a group of patients who did not take any of this medication, no difference was found in developing iron deficiency (OR=2.27 [95% CI 0.19-27.52]; $p=0.52$). An overview of the different associations is shown in table 2.

[Insert table 2]

Oral challenge test

An oral iron challenge test has been performed in 23 patients (1 men and 22 women) suffering from iron deficiency post-RYGB (mean age 44 years, SD 11 years) with a mean ferritin of 7.7 µg/L. As shown in figure 2, there was only one patient who showed sufficient iron absorption (change in serum iron concentration > 80 µg/dL). In four patients, the difference in serum iron concentration before and after the administration of the oral iron supplement was even lower than 20 µg/dL.

[Insert figure 2]

Discussion

Development of iron deficiency and predisposing factors

Thirty seven percent of patients developed iron deficiency at some point after-RYGB. Female gender, young age, poor preoperative iron status, vitamin B12 deficiency and time after surgery were risk factors for the development of iron deficiency after RYGB. In our study, iron deficiency was more prevalent in women than in men which might be explained by menstrual loss in premenopausal women. Menstruation is often impaired in obese women prior to surgery, but usually resumes after RYGB contributing to iron loss and anemia [13;16].

In line with the results of previous studies, we showed that iron deficiency is not only more prevalent in younger patients before bariatric surgery, but that young age also predisposes to iron deficiency after RYGB [17].

Another interesting finding is that pre-operative poor iron status predisposes to iron deficiency after RYGB. This result clearly illustrates the need for an appropriate nutritional evaluation and screening of iron deficiency before RYGB. Consequently, patients should already be treated for iron deficiency before surgery to reduce the probability for developing postoperative iron deficiency and its possible complications [4;18]. We also found that patients with vitamin B12 deficiency were also more likely to have iron deficiency. The link between iron and vitamin B12 deficiency can be explained by the reduced secretion of gastric acid and the decreased consumption of meat. Previous work of Avinoah et al indicates that decreased meat consumption is probably the major factor that contributes to the development of iron and vitamin B12 deficiency after RYGB [11].

As shown, the risk of developing iron deficiency increases over time: two years post-RYGB there were significantly more patients with iron deficiency compared to baseline. This is not surprising, as after RYGB, body iron stores gradually decrease [6;18]. As a matter of fact,

iron deficiency and subsequent anemia may develop years after the surgery. For that reason, patients require a lifelong follow-up of hematological and iron parameters, especially menstruating women, pregnant women and adolescents, even after initial repletion of iron [16;19-22].

We found no correlation between developing iron deficiency and the amount of weight loss, which is in line with a study of Avinoah et al [11]. Furthermore, there was no correlation between developing iron deficiency and vitamin D deficiency, nor with the use of proton pump inhibitors, H₂-antagonists or antacids. Theoretically, these drugs may increase the risk of developing iron deficiency, as they reduce the acid secretion in the stomach and subsequent iron absorption [4]. A possible explanation for this lack of effect is that after RYGB the stomach is much smaller, which is associated with a reduced acid secretion. Therefore, these drugs may have less impact on acid secretion and iron absorption in patients after RYGB than in patients with a normal size of stomach, but this requires further investigation.

Unfortunately, we have no information on the use of vitamin supplements by the patients studied. This type of information is difficult to collect and can only be done in a prospective trial. Moreover, even when vitamins have been prescribed, compliance is very low.

Absorption of oral iron supplements

In the oral challenge test, only one patient had an increase in plasma iron concentrations of more than 80 µg/dL after the administration of 100 mg iron sulphate. This means that in almost all patients who developed severe iron deficiency post-RYGB, the absorption of oral iron supplements is impaired. Previous studies have also shown that the absorption capacity for iron is reduced after RYGB and that oral iron supplements are often inadequate to correct iron deficiency [19-22]. However, to our knowledge, this is the first report of oral iron

absorption tests in patients with severe iron deficiency after RYGB, demonstrating that the development of iron deficiency post-RYGB is largely due to an insufficient absorption of iron. Therefore we support the advice from other papers to switch oral iron supplements to parenteral iron therapy with iron dextran, ferric gluconate, or ferric sucrose if oral treatment is ineffective to correct iron deficiency [19;21]. We do not know whether the absorption of oral iron supplements is also impaired in patients who do not develop iron deficiency after RYGB. Furthermore, a comparison of absorption of iron before and after surgery is not possible with these data, as the oral iron absorption tests have only been performed in patients after RYGB. So, further research on the absorption of oral iron is needed in order to determine whether it is effective to treat iron deficiencies post-RYGB initially with oral supplements or whether it is more useful for these patients to be directly treated with an intravenous formulation of iron to correct iron deficiency.

Conclusions

Iron deficiency is a frequent complication after RYGB, necessitating a good follow-up of these patients. Female gender, young-age, pre-operative poor iron status, vitamin B12 deficiency and the time post-RYGB are predisposing factors for the development of iron deficiency. Iron supplementation seems essential in this population, but the effect of oral tablets may be limited as absorption of oral iron supplements is insufficient post-RYGB.

Acknowledgements

Ina Gesquiere receives a PhD scholarship from the Agency for Innovation by Science and Technology, Flanders, IWT-111328. The authors declare no conflict of interest.

References

1. WHO. Obesity and overweight. 2012. Fact Sheet No.311.
<http://www.who.int/mediacentre/factsheets/fs311/en/> Last consulted 10/05/2013.
2. Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. *Health Technol Assess*. 2009;13(41):1-357.
3. Decker GA, Swain JM, Crowell MD, et al. Gastrointestinal and nutritional complications after bariatric surgery. *Am J Gastroenterol*. 2007;102(11):2571-80.
4. Aarts EO, Van WB, Janssen IM, et al. Prevalence of Anemia and Related Deficiencies in the First Year following Laparoscopic Gastric Bypass for Morbid Obesity. *J Obes*. 2012. doi: 10.1155/2012/193705.
5. Buchwald H, Ikramuddin S, Dorman RB, et al. Management of the metabolic/bariatric surgery patient. *Am J Med*. 2011;124(12):1099-105.
6. Skroubis G, Sakellaropoulos G, Pougouras K, et al. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. *Obes Surg*. 2002;12(4):551-8.
7. Bordalo LA, Teixeira TF, Bressan J, et al. [Bariatric surgery: how and why to supplement]. *Rev Assoc Med Bras*. 2011;57(1):113-20.
8. Brolin RE, Gorman JH, Gorman RC, et al. Are vitamin B12 and folate deficiency clinically important after roux-en-Y gastric bypass? *J Gastrointest Surg*. 1998;2(5):436-42.
9. Ruz M, Carrasco F, Rojas P, et al. Iron absorption and iron status are reduced after Roux-en-Y gastric bypass. *Am J Clin Nutr*. 2009;90(3):527-32.

10. Brolin RE, Gorman JH, Gorman RC, et al. Prophylactic iron supplementation after Roux-en-Y gastric bypass: a prospective, double-blind, randomized study. *Arch Surg.* 1998;133(7):740-4.
11. Avinoah E, Ovnat A, Charuzi I. Nutritional status seven years after Roux-en-Y gastric bypass surgery. *Surgery.* 1992;111(2):137-42.
12. Ruz M, Carrasco F, Rojas P, et al. Heme- and nonheme-iron absorption and iron status 12 mo after sleeve gastrectomy and Roux-en-Y gastric bypass in morbidly obese women. *Am J Clin Nutr.* 2012;96(4):810-7.
13. Aills L, Blankenship J, Buffington C, et al. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. *Surg Obes Relat Dis.* 2008;4(5 Suppl):S73-108.
14. Joosten E, Vander EB, Billen J. Small-dose oral iron absorption test in anaemic and non-anaemic elderly hospitalized patients. *Eur J Haematol* 1997;58(2):99-103.
15. Rubin DB. Inference and missing data. *Biometrika.* 1976;63:581-592.
16. Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. *Am J Hematol.* 2008;83(5):403-9.
17. Flancbaum L, Belsley S, Drake V, et al. Preoperative nutritional status of patients undergoing Roux-en-Y gastric bypass for morbid obesity. *J Gastrointest Surg.* 2006;10(7):1033-7.
18. Ziegler O, Sirveaux MA, Brunaud L, et al. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. *Diabetes Metab.* 2009;35(6 Pt 2):544-57.
19. Varma S, Baz W, Badine E, et al. Need for parenteral iron therapy after bariatric surgery. *Surg Obes Relat Dis.* 2008;4(6):715-9.

20. Shikora SA, Kim JJ, Tarnoff ME. Nutrition and gastrointestinal complications of bariatric surgery. *Nutr Clin Pract*. 2007;22(1):29-40.
21. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. *Obesity* (Silver Spring). 2009;17 Suppl 1:S1-70, v.
22. Defilipp Z, Lister J, Gagne D, et al. Intravenous iron replacement for persistent iron deficiency anemia after Roux-en-Y gastric bypass. *Surg Obes Relat Dis*. 2012

Figure legends

Fig. 1 Predicted probability of ferritin deficiency over time (with indication of 95% confidence interval).

Fig. 2 The estimation of the extent of the intestinal iron absorption (expressed as the difference between the highest serum iron concentration after the administration of 100 mg $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ and the serum concentration at $t=0$) for the 23 individuals who received the oral challenge test (including age (years) and serum ferritin levels ($\mu\text{g/L}$) (between brackets)).

Table 1 Summary statistics, shown as mean (standard deviation).

	Before surgery (n=130)	6 months after RYGB (n=107)	1 year after RYGB (n=90)	2 years after RYGB (n=55)	3 years after RYGB (n=44)	4 years after RYGB (n=27)	5 years after RYGB (n=19)
Gender	99♀, 31 ♂	86♀, 21 ♂	67♀, 23♂	39♀, 16♂	33♀, 11♂	18♀, 9♂	15♀, 4 ♂
Age (years)	43.1(12.0)	42.2(11.4)	42.1(12.0)	44.3(12.0)	42.4(12.8)	43.6(13.6)	41.2(11.7)
Ferritin (µg/L)	101.7(115.7)	81.3(78.9)	76.9(84.0)	66.3(70.8)	35.6(54.1)	56.2(83.9)	38.4(46.5)
Hemoglobin (g/dL)	14.0(1.5)	13.4(1.8)	13.3(1.3)	13.3(1.5)	13.5(1.5)	13.5(1.0)	13.5(1.3)
Weight (kg)	117.6(17.0)	86.5(12.5)	80.2(14.5)	84.8(18.6)	90.2(16.0)	98.7(5.5)	75.4(5.2)
BMI (kg/m²)	42.0(4.9)	30.9(3.7)	28.6(4.1)	29.5(5.2)	31.6(4.6)	36.5(1.9)	26.7(1.8)
Vitamin B12 (ng/mL)	301.0(199.5)	270.9(189.3)	264.5(148.0)	266.8(166.4)	317.2(268.4)	261.5(146.0)	361.4(287.5)
Vitamin D (µg/L)	11.2(13.3)	21.0(13.0)	20.2(12.9)	17.8(11.1)	19.7(11.4)	21.4(13.9)	22.3(17.5)

Table 2 Association between the development of iron deficiency and other parameters.

Parameters	OR	95% Confidence interval	p-value
Gender: male versus female	0.18	0.04 - 0.73	0.0017
Age: 1 year increase	0.94	0.90 - 0.99	0.012
Baseline ferritin deficiency	19.49	3.96 - 95.99	0.0004
Vitamin B12 deficiency	3.78	1.74 - 8.21	0.0009
Time after surgery: increase by month	1.06	1.03 - 1.08	<0.0001
Weight loss	0.98	0.96 - 1.01	0.1271
Vitamin D deficiency	0.60	0.20 - 1.80	0.3620
Consumption of antacids: presence versus absence	2.27	0.19 – 27.52	0.5179